TD Cowen analyst Tyler Van Buren has maintained their bullish stance on GILD stock, giving a Buy rating today. Tyler Van Buren’s rating ...

Leerink upgraded Gilead (GILD) to Outperform from Market Perform with a price target of $96, up from $74. The stock has appreciated following ...

New video upsets the old notion that these birds of paradise use wing clapping to make percussive sounds while courting.

When 10-year-old Samuel Henderson decided to share his bird calls at a school talent show this past May, he wasn’t nervous at all. In fact, in his mind, he was playing to a much larger audience than ...

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often ...

Mark Fielder does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations beyond ...

The Healey administration has tapped Kirk Taylor, a longtime Boston-area biotech executive, to run the quasi-public Massachusetts Life Sciences Center. The life sciences center’s board approved ...

Gilead Sciences GILD underwent analysis by 11 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The following table provides a quick overview of their ...

International AIDS Society, an association of HIV/AIDS professionals, applauded moves by Gilead Sciences, a biopharma company, to make the generic injectable lenacapavir for HIV prevention widely ...

Oct 3 (Reuters) - Gilead Sciences (GILD.O), opens new tab said on Thursday it would donate about 5,000 vials of its antiviral drug remdesivir to the Rwanda Medical Supply for emergency use in ...

For this we must commend the drug’s originator Gilead Sciences. The injection, taken just twice a year, eradicated HIV infection risk for the straight women who were part of the trial.